Stephan Schann, PhD, is in charge of research activities at Domain Therapeutics (www.domaintherapeutics.com), a biopharmaceutical company focusing on GPCR drug discovery and early development. He is managing different projects from the gene to the optimized lead, such as the mGluR4 PAM program for Parkinson’s disease, partnered with Prexton Therapeutics, as well as the mGluR2 NAM or mGluR3 PAM programs for Parkinson’s disease. He is also responsible for DTect-All™ and BioSens-All™, the two proprietary technological platforms used for drug discovery on challenging GPCRs.
Before, Dr. Schann spent six years at Faust Pharmaceuticals, a CNS clinical biopharmaceutical company, where he set up the medicinal chemistry activity. Prior to his position at Faust Pharmaceuticals, he was team leader at EvotecOAI, Abingdon, UK from 2001 to 2003. Dr. Schann received his PhD from the University de Strasbourg, France in 2001.